Research

LIke ThisLIke ThisLIke This

Matthew M.  Heeney, MD

Matthew M. Heeney
Research Center:
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Department:
Medicine Research
Division
Hematology/Oncology Research
Hospital Title:
Associate Chief, Hematology; Director, Sickle Cell Program
Academic Title:
Assistant Professor of Pediatrics, Harvard Medical School
Research Focus Area:
Sickle cell disorders
Contact:
617-355-7700
Contact Via Email
Send an email to SendYour Name*Your Email Address*Subject*Comments*

Research Overview

Dr. Heeney conducts clinical research focused on sickle cell disorders and their treatment. He has been the Children's Hospital Boston Principal Investigator for several clinical trial consortia including the former Boston Sickle Cell Disease Research Network (SCDCRN), and Boston Comprehensive Sickle Cell Center (CSCC). He is also the Site Investigator for the multicenter SWiTCH and TWiTCH trials which are exploring the use of Hydroxyurea as an alternative to chronic transfusion for stroke prevention. He is also involved in early phase trials of prasugrel and regadenoson in sickle cell disease.

Dr. Heeney also conducts translational research in inherited disorders of iron homeostasis in humans. In particular he is interested in investigating the genetic basis inherited disorders of iron deficiency, sideroblastic anemia and iron overload.

Goals of Dr. Heeney's work include: to improve the understanding of the pathophysiology and treatment of sickle cell anemia through multicenter clinical trials and to elucidate the genetic basis of iron homeostasis and its role in human disease.

About Matthew Heeney

Dr. Heeney received his MD at the University of Calgary, Alberta, completed his residency at Montreal Children's Hospital, McGill University, and a pediatric hemotology/oncology fellowship at Duke University.

Publications

Publications powered by Harvard Catalyst Profiles
  1. Brendel C, Guda S, Renella R, Bauer DE, Canver MC, Kim YJ, Heeney MM, Klatt D, Fogel J, Milsom MD, Orkin SH, Gregory RI, Williams DA. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. J Clin Invest. 2016 Oct 3; 126(10):3868-3878.
  2. Lichtenstein DA, Crispin AW, Sendamarai AK, Campagna DR, Schmitz-Abe K, Sousa CM, Kafina MD, Schmidt PJ, Niemeyer CM, Porter J, May A, Patnaik MM, Heeney MM, Kimmelman A, Bottomley SS, Paw BH, Markianos K, Fleming MD. A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia. Blood. 2016 Oct 13; 128(15):1913-1917.
  3. Heeney MM, Hoppe CC, Rees DC. Prasugrel for Sickle Cell Vaso-Occlusive Events. N Engl J Med. 2016 Jul 14; 375(2):185-6.
  4. Tubman VN, Marshall R, Jallah W, Guo D, Ma C, Ohene-Frempong K, London WB, Heeney MM. Newborn Screening for Sickle Cell Disease in Liberia: A Pilot Study. Pediatr Blood Cancer. 2016 Apr; 63(4):671-6.
  5. Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. N Engl J Med. 2016 Feb 18; 374(7):625-35.
  6. Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016 Feb 13; 387(10019):661-70.
  7. Englum BR, Rothman J, Leonard S, Reiter A, Thornburg C, Brindle M, Wright N, Heeney MM, Jason Smithers C, Brown RL, Kalfa T, Langer JC, Cada M, Oldham KT, Scott JP, St Peter SD, Sharma M, Davidoff AM, Nottage K, Bernabe K, Wilson DB, Dutta S, Glader B, Crary SE, Dassinger MS, Dunbar L, Islam S, Kumar M, Rescorla F, Bruch S, Campbell A, Austin M, Sidonio R, Blakely ML, Rice HE. Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. J Pediatr Surg. 2016 Jan; 51(1):122-7.
  8. Schmitz-Abe K, Ciesielski SJ, Schmidt PJ, Campagna DR, Rahimov F, Schilke BA, Cuijpers M, Rieneck K, Lausen B, Linenberger ML, Sendamarai AK, Guo C, Hofmann I, Newburger PE, Matthews D, Shimamura A, Snijders PJ, Towne MC, Niemeyer CM, Watson HG, Dziegiel MH, Heeney MM, May A, Bottomley SS, Swinkels DW, Markianos K, Craig EA, Fleming MD. Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9. Blood. 2015 Dec 17; 126(25):2734-8.
  9. Hoppe CC, Styles L, Heath LE, Zhou C, Jakubowski JA, Winters KJ, Brown PB, Rees DC, Heeney MM. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy. Pediatr Blood Cancer. 2016 Feb; 63(2):299-305.
  10. Wood JC, Pressel S, Rogers ZR, Odame I, Kwiatkowski JL, Lee MT, Owen WC, Cohen AR, St Pierre T, Heeney MM, Schultz WH, Davis BR, Ware RE. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. Am J Hematol. 2015 Sep; 90(9):806-10.
  11. Show all
  12. Aygun B, Mortier NA, Kesler K, Lockhart A, Schultz WH, Cohen AR, Alvarez O, Rogers ZR, Kwiatkowski JL, Miller ST, Sylvestre P, Iyer R, Lane PA, Ware RE. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. Br J Haematol. 2015 Apr; 169(2):262-6.
  13. Styles L, Heiselman D, Heath LE, Moser BA, Small DS, Jakubowski JA, Zhou C, Redding-Lallinger R, Heeney MM, Quinn CT, Rana SR, Kanter J, Winters KJ. Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study. J Pediatr Hematol Oncol. 2015 Jan; 37(1):1-9.
  14. Rice HE, Englum BR, Rothman J, Leonard S, Reiter A, Thornburg C, Brindle M, Wright N, Heeney MM, Smithers C, Brown RL, Kalfa T, Langer JC, Cada M, Oldham KT, Scott JP, St Peter S, Sharma M, Davidoff AM, Nottage K, Bernabe K, Wilson DB, Dutta S, Glader B, Crary SE, Dassinger MS, Dunbar L, Islam S, Kumar M, Rescorla F, Bruch S, Campbell A, Austin M, Sidonio R, Blakely ML. Clinical outcomes of splenectomy in children: report of the splenectomy in congenital hemolytic anemia registry. Am J Hematol. 2015 Mar; 90(3):187-92.
  15. Heeney MM. Iron clad: iron homeostasis and the diagnosis of hereditary iron overload. Hematology Am Soc Hematol Educ Program. 2014 Dec 5; 2014(1):202-9.
  16. Chakraborty PK, Schmitz-Abe K, Kennedy EK, Mamady H, Naas T, Durie D, Campagna DR, Lau A, Sendamarai AK, Wiseman DH, May A, Jolles S, Connor P, Powell C, Heeney MM, Giardina PJ, Klaassen RJ, Kannengiesser C, Thuret I, Thompson AA, Marques L, Hughes S, Bonney DK, Bottomley SS, Wynn RF, Laxer RM, Minniti CP, Moppett J, Bordon V, Geraghty M, Joyce PB, Markianos K, Rudner AD, Holcik M, Fleming MD. Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood. 2014 Oct 30; 124(18):2867-71.
  17. Heeney MM, Cohen AR. Iron disorders. Hematol Oncol Clin North Am. 2014 Aug; 28(4):ix-x.
  18. Helton KJ, Adams RJ, Kesler KL, Lockhart A, Aygun B, Driscoll C, Heeney MM, Jackson SM, Krishnamurti L, Miller ST, Sarnaik SA, Schultz WH, Ware RE. Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood. 2014 Aug 7; 124(6):891-8.
  19. Heeney MM, Finberg KE. Iron-refractory iron deficiency anemia (IRIDA). Hematol Oncol Clin North Am. 2014 Aug; 28(4):637-52, v.
  20. Campagna DR, de Bie CI, Schmitz-Abe K, Sweeney M, Sendamarai AK, Schmidt PJ, Heeney MM, Yntema HG, Kannengiesser C, Grandchamp B, Niemeyer CM, Knoers NV, Swart S, Marron G, van Wijk R, Raymakers RA, May A, Markianos K, Bottomley SS, Swinkels DW, Fleming MD. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations. Am J Hematol. 2014 Mar; 89(3):315-9.
  21. Ogunlesi F, Heeney MM, Koumbourlis AC. Systemic corticosteroids in acute chest syndrome: friend or foe? Paediatr Respir Rev. 2014 Mar; 15(1):24-7.
  22. Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol. 2013 Nov; 88(11):932-8.
  23. Baskin MN, Goh XL, Heeney MM, Harper MB. Bacteremia risk and outpatient management of febrile patients with sickle cell disease. Pediatrics. 2013 Jun; 131(6):1035-41.
  24. Wiseman DH, May A, Jolles S, Connor P, Powell C, Heeney MM, Giardina PJ, Klaassen RJ, Chakraborty P, Geraghty MT, Major-Cook N, Kannengiesser C, Thuret I, Thompson AA, Marques L, Hughes S, Bonney DK, Bottomley SS, Fleming MD, Wynn RF. A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood. 2013 Jul 4; 122(1):112-23.
  25. Frelinger AL, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, Barnard MR, Heeney MM, Michelson AD. Platelet activation and inhibition in sickle cell disease (pains) study. Platelets. 2014; 25(1):27-35.
  26. Chawla A, Sprinz PG, Welch J, Heeney M, Usmani N, Pashankar F, Kavanagh P. Weight status of children with sickle cell disease. Pediatrics. 2013 Apr; 131(4):e1168-73.
  27. Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatr Blood Cancer. 2012 Aug; 59(2):365-71.
  28. Ware RE, Helms RW. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012 Apr 26; 119(17):3925-32.
  29. Stewart AK, Shmukler BE, Vandorpe DH, Rivera A, Heneghan JF, Li X, Hsu A, Karpatkin M, O'Neill AF, Bauer DE, Heeney MM, John K, Kuypers FA, Gallagher PG, Lux SE, Brugnara C, Westhoff CM, Alper SL. Loss-of-function and gain-of-function phenotypes of stomatocytosis mutant RhAG F65S. Am J Physiol Cell Physiol. 2011 Dec; 301(6):C1325-43.
  30. Sobota A, Graham DA, Neufeld EJ, Heeney MM. Thirty-day readmission rates following hospitalization for pediatric sickle cell crisis at freestanding children's hospitals: risk factors and hospital variation. Pediatr Blood Cancer. 2012 Jan; 58(1):61-5.
  31. Sobota A, Neufeld EJ, Sprinz P, Heeney MM. Transition from pediatric to adult care for sickle cell disease: results of a survey of pediatric providers. Am J Hematol. 2011 Jun; 86(6):512-5.
  32. Vichinsky E, Bernaudin F, Forni GL, Gardner R, Hassell K, Heeney MM, Inusa B, Kutlar A, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol. 2011 Aug; 154(3):387-97.
  33. Heeney MM. Rudolph’s Pediatrics. Iron Deficiency Anemia: Definition, Pathophysiology and Classification. 2011.
  34. Heeney MM. Rudolph’s Pediatrics (Rudolph AM, Rudolph C, First L, Lister G, Gershon AA. Editors). Anemia: Definition, Pathophysiology and Classification. 2011.
  35. George M, Heeney MM, Woolf AD. Encephalopathy from lead poisoning masquerading as a flu-like syndrome in an autistic child. Pediatr Emerg Care. 2010 May; 26(5):370-3.
  36. Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, Johnson CS, Rogers ZR, Smith-Whitley K, Wang WC, Telen MJ. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol. 2010 Jan; 85(1):6-13.
  37. Sobota A, Graham DA, Heeney MM, Neufeld EJ. Corticosteroids for acute chest syndrome in children with sickle cell disease: variation in use and association with length of stay and readmission. Am J Hematol. 2010 Jan; 85(1):24-8.
  38. Morrissey LK, Shea JO, Kalish LA, Weiner DL, Branowicki P, Heeney MM. Clinical practice guideline improves the treatment of sickle cell disease vasoocclusive pain. Pediatr Blood Cancer. 2009 Mar; 52(3):369-72.
  39. Steinberg MH. Ohene-Frempong K. Heeney MM. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management (Steinberg MH, Forget BG, Higgs DR, Weatherall DJ. Editors). Clinical and Pathophysiological Aspects of Sickle Cell Anemia. 2009; 437-496.
  40. Hettmer S, Heeney MM. Cefepime-induced neutropenia in a teenager. Pediatr Blood Cancer. 2008 Nov; 51(5):715-6.
  41. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Pediatr Clin North Am. 2008 Apr; 55(2):483-501, x.
  42. Aygun B, McMurray MA, Schultz WH, Kwiatkowski JL, Hilliard L, Alvarez O, Heeney M, Kalinyak K, Lee MT, Miller S, Helms RW, Ware RE. Chronic transfusion practice for children with sickle cell anaemia and stroke. Br J Haematol. 2009 May; 145(4):524-8.
  43. Dover GJ. Heeney MM. Nathan and Oski’s Hematology of Infancy and Childhood (Nathan DG, Orkin SH, Ginsburg D, Look AT. Editors). Sickle Cell Disease. 2008; 949-1014.
  44. Mazumdar M, Heeney MM, Sox CM, Lieu TA. Preventing stroke among children with sickle cell anemia: an analysis of strategies that involve transcranial Doppler testing and chronic transfusion. Pediatrics. 2007 Oct; 120(4):e1107-16.
  45. Tubman VN, Bennett CM, Luo HY, Chui DH, Heeney MM. Sickle cell disease caused by Hb S/Québec-CHORI: treatment with hydroxyurea and response. Pediatr Blood Cancer. 2007 Aug; 49(2):207-10.
  46. Masiello D, Heeney MM, Adewoye AH, Eung SH, Luo HY, Steinberg MH, Chui DH. Hemoglobin SE disease: a concise review. Am J Hematol. 2007 Jul; 82(7):643-9.
  47. Tubman VN, Smoot L, Heeney MM. Acquired immune cytopenias post-cardiac transplantation respond to rituximab. Pediatr Blood Cancer. 2007 Mar; 48(3):339-44.
  48. Heeney MM. Management of Sickle Cell Disease,. Comprehensive Pediatric Hospital Medicine (Zaoutis LD, Chiang VW). 2007; 731-737.
  49. Duncan C. Heeney MM. Hematologic Disorders. Manual of Pediatric Therapeutics (Greenes DS, Graeff JW.). 2007; 466-499.
  50. Luo HY, Heeney M, Wang WC, Eung SH, Ware RE, Steinberg MH, Chui DH. Hemoglobinopathies mimicking Hb S/beta-thalassemia: Hb S/S with alpha-thalassemia and Hb S/Volga. Am J Hematol. 2006 May; 81(5):361-5.
  51. Heeney MM. Risk of cholelithiasis in sickle cell anemia. Haematologica. 2005 Feb; 90(2):147.
  52. Heeney MM, Andrews NC. Iron homeostasis and inherited iron overload disorders: an overview. Hematol Oncol Clin North Am. 2004 Dec; 18(6):1379-403, ix.
  53. Heeney MM, Whorton MR, Howard TA, Johnson CA, Ware RE. Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol. 2004 Mar; 26(3):179-84.
  54. Heeney MM, Zimmerman SA, Ware RE. Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr. 2003 Nov; 143(5):662-5.
  55. Heeney MM, Ormsbee SM, Moody MA, Howard TA, DeCastro CM, Ware RE. Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria. Mol Genet Metab. 2003 Apr; 78(4):291-4.
  56. Heeney MM, Howard TA, Zimmerman SA, Ware RE. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. J Lab Clin Med. 2003 Apr; 141(4):279-82.
  57. Heeney MM. Ware RE. Diagnostic Approach to Sickle Hemoglobinopathies. Practical Algorithms in Pediatric Hematology-Oncology (Sills R). 2003.
  58. Ware RE. Heeney MM. Pickens CV. DeCastro CM. Howard TA. A multi-step model for the pathogenesis and evolution of PNH. Paroxysmal Nocturnal Hemoglobinuria (PNH) and Related Disorders. 2003; 41-54.
  59. Heeney MM. Ware RE. . Newborn Screening for Hemoglobinopathies. Practical Algorithms in Pediatric Hematology Oncology (Sills R.). 2003.
  60. Heeney MM, Delgrosso K, Robinson R, Johnson CA, Daeschner CW, Campbell TA, Surrey S, Ware RE. Interpretation of fetal hemoglobin only on newborn screening for hemoglobinopathy. J Pediatr Hematol Oncol. 2002 Aug-Sep; 24(6):499-502.
  61. Zhang XL, Seong R, Piracha R, Larijani M, Heeney M, Parnes JR, Chamberlain JW. Distinct stage-specific cis-active transcriptional mechanisms control expression of T cell coreceptor CD8 alpha at double- and single-positive stages of thymic development. J Immunol. 1998 Sep 1; 161(5):2254-66.
  62. Kushida MM, Dey A, Zhang XL, Campbell J, Heeney M, Carlyle J, Ganguly S, Ozato K, Vasavada H, Chamberlain JW. A 150-base pair 5' region of the MHC class I HLA-B7 gene is sufficient to direct tissue-specific expression and locus control region activity: the alpha site determines efficient expression and in vivo occupancy at multiple cis-active sites throughout this region. J Immunol. 1997 Nov 15; 159(10):4913-29.
  63. "Retrospective Assessment of Utilisation and Effect on Management of Echocardiography in Patients with Suspected Mitral Valve Prolapse" . Supervisor: D. Isaac, MD Year II Research Elective, Faculty of Medicine, University of Calgary, Calgary, AB . 1996.
  64. "The Mechanisms of Scaphoid Fracture and Relation to Hand of Dominance, Activity During Injury, and Anatomical Site of Fracture: A Retrospective Analysis" . Year I Research Elective, Faculty of Medicine, University of Calgary, Calgary, AB. 1995.
  65. "Distinct Regulatory Mechanisms Control CD8 Expression in CD4+/CD8+ Thymocytes vs. CD4-/CD8- in vivo". Oral Presentation, Hospital for Sick Children Research Institute, Toronto, ON. 1992.
  66. "Renal Expression of Urokinase-type Plasminogen Activator is Decreased in Experimental Nephrosis.". Oral Presentation, Hospital for Sick Children Research Institute, Toronto, ON. 1991.
  67. Smith ER, McClain CD, Heeney M, Scott RM. Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. Neurosurg Focus. 2009 Apr; 26(4):E10.
  68. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, Bouatia-Naji N, Langenberg C, Prokopenko I, Stolerman E, Sandhu MS, Heeney MM, Devaney JM, Reilly MP, Ricketts SL, Stewart AF, Voight BF, Willenborg C, Wright B, Altshuler D, Arking D, Balkau B, Barnes D, Boerwinkle E, Böhm B, Bonnefond A, Bonnycastle LL, Boomsma DI, Bornstein SR, Böttcher Y, Bumpstead S, Burnett-Miller MS, Campbell H, Cao A, Chambers J, Clark R, Collins FS, Coresh J, de Geus EJ, Dei M, Deloukas P, Döring A, Egan JM, Elosua R, Ferrucci L, Forouhi N, Fox CS, Franklin C, Franzosi MG, Gallina S, Goel A, Graessler J, Grallert H, Greinacher A, Hadley D, Hall A, Hamsten A, Hayward C, Heath S, Herder C, Homuth G, Hottenga JJ, Hunter-Merrill R, Illig T, Jackson AU, Jula A, Kleber M, Knouff CW, Kong A, Kooner J, Köttgen A, Kovacs P, Krohn K, Kühnel B, Kuusisto J, Laakso M, Lathrop M, Lecoeur C, Li M, Li M, Loos RJ, Luan J, Lyssenko V, Mägi R, Magnusson PK, Mälarstig A, Mangino M, Martínez-Larrad MT, März W, McArdle WL, McPherson R, Meisinger C, Meitinger T, Melander O, Mohlke KL, Mooser VE, Morken MA, Narisu N, Nathan DM, Nauck M, O'Donnell C, Oexle K, Olla N, Pankow JS, Payne F, Peden JF, Pedersen NL, Peltonen L, Perola M, Polasek O, Porcu E, Rader DJ, Rathmann W, Ripatti S, Rocheleau G, Roden M, Rudan I, Salomaa V, Saxena R, Schlessinger D, Schunkert H, Schwarz P, Seedorf U, Selvin E, Serrano-Ríos M, Shrader P, Silveira A, Siscovick D, Song K, Spector TD, Stefansson K, Steinthorsdottir V, Strachan DP, Strawbridge R, Stumvoll M, Surakka I, Swift AJ, Tanaka T, Teumer A, Thorleifsson G, Thorsteinsdottir U, Tönjes A, Usala G, Vitart V, Völzke H, Wallaschofski H, Waterworth DM, Watkins H, Wichmann HE, Wild SH, Willemsen G, Williams GH, Wilson JF, Winkelmann J, Wright AF, Zabena C, Zhao JH, Epstein SE, Erdmann J, Hakonarson HH, Kathiresan S, Khaw KT, Roberts R, Samani NJ, Fleming MD, Sladek R, Abecasis G, Boehnke M, Froguel P, Groop L, McCarthy MI, Kao WH, Florez JC, Uda M, Wareham NJ, Barroso I, Meigs JB. Common variants at 10 genomic loci influence hemoglobin A1(C) levels via glycemic and nonglycemic pathways. Diabetes. 2010 Dec; 59(12):3229-39.
  69. Finberg KE, Heeney MM, Campagna DR, Aydinok Y, Pearson HA, Hartman KR, Mayo MM, Samuel SM, Strouse JJ, Markianos K, Andrews NC, Fleming MD. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008 May; 40(5):569-71.
  70. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am. 2010 Feb; 24(1):199-214.
  71. Anderson DS, Heeney MM, Roth U, Menzel C, Fleming MD, Steen H. High-throughput matrix-assisted laser desorption ionization-time-of-flight mass spectrometry method for quantification of hepcidin in human urine. Anal Chem. 2010 Feb 15; 82(4):1551-5.
  72. Grace RF, Su H, Sena L, Poussaint TY, Heeney MM, Gutierrez A. Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. Am J Hematol. 2010 Feb; 85(2):135-7.
  73. McCarville MB, Rogers ZR, Sarnaik S, Scott P, Aygun B, Hilliard L, Lee MT, Kalinyak K, Owen W, Garro J, Schultz W, Yovetich N, Ware RE. Effects of chronic transfusions on abdominal sonographic abnormalities in children with sickle cell anemia. J Pediatr. 2012 Feb; 160(2):281-285.e1.
  74. Cattivelli K, Campagna DR, Schmitz-Abe K, Heeney MM, Yaish HM, Caruso Brown AE, Kearney S, Walkovich K, Markianos K, Fleming MD, Neufeld EJ. Ringed sideroblasts in ß-thalassemia. Pediatr Blood Cancer. 2016 Nov 3.
LIke ThisLIke ThisLIke This

RELATED RESEARCH CENTER

Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

Dana-Farber/Boston Children's Cancer and Blood Disorders Center is one of the top research centers in the world for pediatric cancers and blood diseases. It brings together laboratory scientists and clinical researchers from Dana-Farber Cancer Institute and Boston Children’s Hospital in a single program. We investigate pediatric cancers and non-malignant blood disorders from every angle—from examining cells under the microscope to tracking the effectiveness of current drug regimens using the most advanced molecular methods—so that we can create better treatments for children seen here and around the world.

Learn more
Close